Objective: Cutaneous manifestations of pediatric systemic lupus erythematosus cause significant morbidity. Lenalidomide, a thalidomide analogue, has shown promise treating cutaneous lupus erythematosus in adults. Our objective was to evaluate lenalidomide's efficacy and safety in treating refractory cutaneous manifestations of pediatric systemic lupus erythematosus. Methods: We performed a retrospective chart review of 10 adolescents who received lenalidomide for recalcitrant cutaneous lupus erythematosus. Information was gathered at drug initiation and 6-month follow-up. The Wilcoxon matched-pairs signed-rank test was used to assess change in quantitative parameters of disease activity. Results: Nine subjects were girls and six were African-American. Indications for lenalidomide treatment included alopecia, nasal and oral ulcers, extensive malar rash, discoid lesions, bullous lesions, panniculitis, cutaneous vasculitis, and Raynaud's phenomenon with digital ulcerations. Within 6 months, all patients demonstrated complete or near resolution based on physician report. Prednisone dose decreased from a mean 23.5 mg (SDAE 13.3) to 12.25 mg (SDAE 9.2) (P¼ 0.008). Sedimentation rate decreased from a mean 29 mm/hour (SDAE 31.5) to 17 mm/hour (SDAE 18.1) (P¼ 0.004). Lenalidomide was well tolerated. Conclusion: Lenalidomide is an effective and safe treatment for a spectrum of dermatological conditions in pediatric systemic lupus erythematosus. Its use may allow a reduction in prednisone dose and decreased disfigurement. Prospective study is needed to clarify lenalidomide's role in treating cutaneous manifestations of systemic lupus erythematosus. Lupus (2017) 26, 646-649.
Introduction
Cutaneous manifestations are common in systemic lupus erythematosus (SLE), causing significant morbidity. Skin involvement occurs in up to 85% of patients and can be extensive, disfiguring, and recalcitrant to traditional therapy. 1, 2 The goals of treatment are to reduce activity and minimize damage. Management typically includes a combination of sun protective measures, antimalarials, topical and systemic corticosteroids, and immunosuppressant or immunomodulatory therapies. 3, 4 Thalidomide has proved to be effective in the treatment of cutaneous lupus erythematosus (CLE), but its use is limited by fetal teratogenicity and the potential for peripheral neuropathy. 5, 6 Lenalidomide, a thalidomide analogue, has also shown promise in adults, with greater potency and a more favorable side effect profile compared to thalidomide. [7] [8] [9] [10] Although their mechanism of action is not completely understood, both agents appear to have anti-inflammatory and immunomodulatory properties. 11, 12 The aims of this study were to evaluate and report the safety and clinical efficacy of lenalidomide in the treatment of refractory cutaneous manifestations of pediatric SLE.
Methods
We retrospectively analyzed records of 10 adolescents started on lenalidomide between 2008 and 2013 specifically for treatment of recalcitrant cutaneous manifestations of SLE. Lenalidomide dosing was 5-12.5 mg daily. One subject was initially taking thalidomide 100 mg daily before being switched to lenalidomide. Patients were evaluated at drug initiation and at 6-month follow-up using a standardized case report form. Information collected included race, gender, age and disease manifestations at time of SLE diagnosis, age and cutaneous manifestations at lenalidomide initiation, concurrent medications, prednisone dose, and laboratory parameters, including white blood cell count (WBC), neutrophil count (ANC), lymphocyte count (ALC), and erythrocyte sedimentation rate (ESR).
Quantitative data were expressed as meanAE standard deviation. The Wilcoxon matched-pairs signed-rank test was used to compare quantitative parameters obtained at 6-month evaluation from baseline. Patients with missing values were excluded from that particular analysis. Statistical analyses were performed using GraphPad Prism (Version 6.0; GraphPad Software, Inc., La Jolla, CA, USA). Results were considered significant if P< 0.05. The study protocol was approved by Duke University health system institutional review board.
Results
Nine subjects were girls and six were African-American (Table 1) . Average age at diagnosis was 12.5 years (SD AE 3.3). Average age at lenalidomide initiation was 16.9 years (SD AE 3.8). All subjects started the medication for treatment of skin disease, including scarring alopecia, nasal and oral ulcers, extensive malar rash, diffuse maculopapular eruption, discoid lesions, bullous lesions, panniculitis, and severe Raynaud's phenomenon with digital ulcerations. One patient initially received thalidomide before switching to lenalidomide 28 months later due to complaints of numbness over her anterior shin with a normal electromyogram.
Within the first 6 months of treatment with lenalidomide, all 10 subjects demonstrated excellent response with near or complete resolution of cutaneous manifestations based on physician report. Lenalidomide maintained the remission in skin disease achieved on thalidomide in the one patient. No subject experienced a cutaneous flare on continued lenalidomide therapy. At the time of chart review, mean duration of therapy was 18 months. Prednisone dose was decreased in eight out of 10 of patients (Table 1) , from a mean of 23.5 mg (SD AE 13.3) to a mean of 12.25 mg (SD AE 9.2) at 6 months (P ¼ 0.008). ESR also decreased from a mean of 29 mm/hour (SD AE 31.5) to a mean of 17 mm/hour (SD AE 18.1) at 6 months (P ¼ 0.004).
Only one patient started a new disease-modifying anti-rheumatic drug (azathioprine) during the 6-month follow-up period. The remaining subjects stayed on steady doses of other immunusuppressants. Lenalidomide exhibited a favorable side effect profile, even when used in conjunction with other immunosuppressive agents. There were no significant changes in WBC, ANC, or ALC values from baseline to 6-month follow up (all P > 0.05). We further describe the treatment of two patients with lenalidomide for severe, recalcitrant CLE to illustrate its efficacy and tolerability.
Patient 1
A 13-year-old African American girl was diagnosed with SLE at 11 years of age with lymphopenia, direct Coomb's positive hemolytic anemia, oral ulcers, and positive antinuclear antibodies (ANA), anti-dsDNA, anticardiolipin, and anti-beta-2 glycoprotein antibodies. Lenalidomide 5 mg daily was started for extensive alopecia (Figure 1(a) ) and nasal and oral ulcers refractory to treatment with hydroxychloroquine, oral prednisone, and topical corticosteroids.
The patient demonstrated good clinical response within 6 months with complete hair regrowth after 9 months (Figure 1(b) ) of starting lenalidomide.
Her lenalidomide dose was increased to 10 mg daily after 8 months of treatment for recurrence of panniculitis. Her panniculitis resolved with the higher lenalidomide dose. Over the course of 14 months, her prednisone was successfully tapered from 30 mg daily to 7.5 mg daily without the addition of other immunosuppressive therapy. There were no serious adverse events attributable to the use of lenalidomide.
Patient 2
A 21-year-old Caucasian man was diagnosed with SLE at 16 years of age with malar rash, photosensitivity, nephritis, positive ANA, and positive anti-dsDNA antibody. Lenalidomide 10 mg daily was initiated for extensive malar rash (Figure 2(a) ) and cutaneous vasculitis of the extremities recalcitrant to hydroxychloroquine and oral prednisone. The patient exhibited marked improvement within 1 month (Figure 2(b) ), with complete resolution of cutaneous disease after 6 months of lenalidomide treatment. He was started on azathioprine 100 mg daily and his oral prednisone increased after 5 months of therapy due to serological flare with elevated anti-dsDNA antibody titer and hypocomplementemia, but no flare in skin disease. Prior to the disease flare, his prednisone was successfully tapered from 40 mg daily to 15 mg daily. There were no serious adverse events attributable to the use of lenalidomide.
Conclusions
Skin disease is highly prevalent among children and adolescents with SLE and can be disfiguring. We report our clinical experience with lenalidomide in the treatment of refractory cutaneous manifestations of pediatric SLE. We observed a high rate of near or complete remission in cutaneous disease within 6 months of lenalidomide therapy. Its use also allowed for reductions in prednisone. Lenalidomide was well tolerated and did not cause significant changes in WBC, ANC, or ALC values. Although lenalidomide was extremely effective in treating recalcitrant cutaneous manifestations, it did not prevent systemic disease flare in one patient. The risk and nature of flare in cutaneous disease after lenalidomide withdrawal is also unknown.
Lenalidomide was both effective and safe for the treatment of a spectrum of dermatological conditions in this small, retrospective study in pediatric SLE. It may be used alone or as adjunctive therapy. Prospective study of lenalidomide is needed to clarify its role further in the treatment of cutaneous manifestations of SLE. 
